Brain Tumor
Conditions
Keywords
Brain Tumor, Methylphenidate, Ritalin, Modafinil, Provigil, Fatigue, Concentration
Brief summary
Primary Objective: * To assess the efficacy of immediate release methylphenidate, sustained release methylphenidate, and the novel vigilance enhancing drug modafinil for the improvement of cognitive functioning in patients with brain tumors.
Detailed description
All three drugs used in this clinical research study are widely used stimulants to help cancer patients who have fatigue and problems with concentration. Before treatment starts, you will have a physical exam, including measurement of blood pressure, and neuropsychological and symptom evaluations. The neuropsychological evaluation is made up of tests of attention, memory, speech, and other brain functions, and takes about 30 minutes to complete. The other test evaluates symptoms you may be experiencing, such as fatigue or depression, and takes about 10 minutes to complete. You will be randomly assigned (as in the toss of a coin) to one of three treatment groups. Participants in the first group will receive Immediate Release (IR) methylphenidate. Participants in the second group will receive Sustained Release (SR) methylphenidate. Participants in the third group will receive modafinil. There is an equal chance of being assigned to any of the groups. After you are randomized, you will contact the M. D. Anderson pharmacy to receive your assigned medication. You will receive a total of 5 weeks worth of medication. The extra week of medication is to allow for buffer should there be any conflict in rescheduling the follow-up evaluation. IR methylphenidate is a pill taken twice a day. Both SR methylphenidate and modafinil are pills taken once a day. The amount of the medicine is the same for all three groups. You will take the medication every day for a total of 4 weeks. You will be asked to complete a study calendar, which will be provided by the research staff. In the study calendar, you will be asked to initial after you take the study drug each day, and to record any side effects you may experience. You will be required to return the completed study calendar at the final evaluation visit, along with the empty bottles and any of the study drugs that may be left over. You will remain on treatment for 4 weeks and return for a final evaluation. A follow-up neuropsychological evaluation and evaluation of symptoms will be performed. At the end of the study treatment period, you will be allowed to remain on active treatment if you wish to. You can discuss with your doctor whether to continue on the same medication or to try another one. This is an investigational study. All of the study drugs are FDA approved and currently are used to help brain tumor patients. A total of 75 patients will take part in this study. All will be enrolled at M. D. Anderson.
Interventions
DRUGIR Methylphenidate
10 mg by mouth (PO) twice daily x 4 Weeks
DRUGModafinil
200 mg PO Once Daily x 4 Weeks
DRUGSR Methylphenidate
18 mg PO Once Daily x 4 Weeks
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient diagnosed with a brain tumor, either primary or metastatic 2. Patient had prior radiation treatment to the brain 3. Patient is \> or = 18 years of age 4. Patient has a Karnofsky performance status (KPS) performance of 70 at baseline 5. Patient is using acceptable birth control methods. Female participants (if of child bearing age and sexually active) and male participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control, including abstinence, birth control pills, diaphragm with spermicide, condom with foam or spermicide, vaginal spermicidal suppository or surgical sterilization. 6. Patient must speak and understand English or Spanish 7. Patient has reported cognitive decline and is being considered for stimulant therapy by their neurologist 8. Patient has provided written informed consent to participate in the study prior to enrollment to the study
Exclusion criteria
1. History of hypersensitivity reaction to methylphenidate or modafinil 2. History of severe headaches, glaucoma, major psychiatric diagnosis, narcolepsy, Tourette's syndrome, marked anxiety, tension or agitation 3. History of clinically significant pulmonary or cardiac disease 4. Uncontrolled hypertension: has not been on a stable treatment dose for the past month, or has a systolic pressure consistently greater than 140 mm Hg or diastolic pressure consistently greater than 90 mm Hg 5. Patients with uncontrolled seizures will be excluded 6. Current use of illicit drugs or history of alcohol or drug abuse and/or abuse potential 7. Moderate to severe depression (\> 20 on Beck Depression Inventory II) 8. If taking antidepressants, patient must be on a stable dose 9. Currently taking psychostimulants, Monoamine oxidase (MAO) inhibitors, or anticoagulants 10. Current use of the following herbals or supplements for fatigue relief (dehydroepiandrosterone (DHEA), S-Adenosyl methionine (SAME), ginkgo, ginseng, St. John's Wort) 11. Any coexisting medical condition or are taking any concomitant medication that is likely to interfere with the safe administration of methylphenidate. Any potential interactions or coexisting medical condition not specified by the protocol will be determined by the prescribing physician as being exclusionary or not. 12. Patients currently taking any erythropoietin type drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Processing Speed Change From Baseline in the Trail-making Test Part A Score | Baseline to 4-5 weeks on study medication | 'Trail Making Test Part A' is a neuropsychological test of visual attention and task switching, administered to measure processing speed, timed as participants follow trail made by consecutive numbers (1,2,3, etc.). The test is finished as quickly as possible, and the time taken to complete the test used as the primary performance metric (in seconds). Maximum time allowed is 300 seconds. A lower change score indicates improvement. Participants tested before starting study medication and 4-5 weeks later while on study medication, reflected in a z score (deviations from population mean). |
| Patient Cognitive Test Scores at End of Treatment Period | Baseline to end of Week 4 treatment period | For cognitive assessment, set of widely used standardized psychometric instruments shown to be sensitive to neurotoxic effects of cancer treatment. Measures assess attention span (Digit Span), graphomotor speed (Digit Symbol), memory (Hopkins Verbal Memory Test-Revised), verbal fluency (Controlled Oral Words Association), visual motor scanning speed (Trail Making Test Part A), executive function (Trail Making Test Part B); motor speed and dexterity (Grooved Pegboard). |
Countries
United States
Participant flow
Recruitment details
Recruitment Period: March 2004 - April 2009. All recruiting done at UT MD Anderson Cancer Center, Neuro-Oncology Clinic.
Pre-assignment details
Of the 34 registered patients, one enrolled patient did not join study and therefore was never included in any group assignment.
Participants by arm
| Arm | Count |
|---|---|
| IR Methylphenidate Immediate Release (IR) Methylphenidate 10 mg by mouth (PO) twice daily for 4 weeks | 11 |
| SR Methylphenidate Sustained Release (SR) Methylphenidate 200 mg PO once daily for 4 weeks | 12 |
| Modafinil 18 mg PO once daily for 4 weeks | 10 |
| Total | 33 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 1 | 2 | 3 |
| Overall Study | Progressive Disease | 1 | 0 | 1 |
| Overall Study | Started new medication voiding entry | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | SR Methylphenidate | Modafinil | IR Methylphenidate | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 3 Participants | 0 Participants | 3 Participants |
| Age, Categorical Between 18 and 65 years | 12 Participants | 7 Participants | 11 Participants | 30 Participants |
| Age, Continuous | 41.2 years STANDARD_DEVIATION 10.5 | 53.8 years STANDARD_DEVIATION 12.9 | 45.9 years STANDARD_DEVIATION 10 | 46.6 years STANDARD_DEVIATION 12 |
| Region of Enrollment United States | 12 participants | 10 participants | 11 participants | 33 participants |
| Sex: Female, Male Female | 6 Participants | 4 Participants | 6 Participants | 16 Participants |
| Sex: Female, Male Male | 6 Participants | 6 Participants | 5 Participants | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 11 | 0 / 12 | 0 / 10 |
| serious Total, serious adverse events | 0 / 11 | 0 / 12 | 0 / 10 |
Outcome results
Primary
Mean Processing Speed Change From Baseline in the Trail-making Test Part A Score
'Trail Making Test Part A' is a neuropsychological test of visual attention and task switching, administered to measure processing speed, timed as participants follow trail made by consecutive numbers (1,2,3, etc.). The test is finished as quickly as possible, and the time taken to complete the test used as the primary performance metric (in seconds). Maximum time allowed is 300 seconds. A lower change score indicates improvement. Participants tested before starting study medication and 4-5 weeks later while on study medication, reflected in a z score (deviations from population mean).
Time frame: Baseline to 4-5 weeks on study medication
Population: Analysis were per protocol. The z-score reflects how many standard deviations above or below the population mean a raw score is for each participant.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| IR Methylphenidate | Mean Processing Speed Change From Baseline in the Trail-making Test Part A Score | -4.7 z-scores | Standard Deviation 9.2 |
| SR Methylphenidate | Mean Processing Speed Change From Baseline in the Trail-making Test Part A Score | 0.24 z-scores | Standard Deviation 1 |
| Modafinil | Mean Processing Speed Change From Baseline in the Trail-making Test Part A Score | -3.7 z-scores | Standard Deviation 4.1 |
Primary
Patient Cognitive Test Scores at End of Treatment Period
For cognitive assessment, set of widely used standardized psychometric instruments shown to be sensitive to neurotoxic effects of cancer treatment. Measures assess attention span (Digit Span), graphomotor speed (Digit Symbol), memory (Hopkins Verbal Memory Test-Revised), verbal fluency (Controlled Oral Words Association), visual motor scanning speed (Trail Making Test Part A), executive function (Trail Making Test Part B); motor speed and dexterity (Grooved Pegboard).
Time frame: Baseline to end of Week 4 treatment period